Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer

OBJECTIVE: In the phase II ALTER-1202 (NCT03059797) trial, anlotinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced small-cell lung cancer (SCLC) who underwent at least 2 previous chemotherapy cycles, when compared with a placebo group. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cuicui, Wang, Jing, Wang, Xinyue, Meng, Zhaoting, Cheng, Ying, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425186/
https://www.ncbi.nlm.nih.gov/pubmed/34302324
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425186/
https://www.ncbi.nlm.nih.gov/pubmed/34302324
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0727

Ejemplares similares